SYNLOGIC, INC. Operating Lease Cost
SYNLOGIC, INC. (SYBX) reported Operating Lease Cost of $1.58 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2025-03-06
- SYNLOGIC, INC. operating lease, cost for the quarter ending 2019-12-31 was $907.00K.
- SYNLOGIC, INC. operating lease, cost for the quarter ending 2019-09-30 was $907.00K.
- SYNLOGIC, INC. operating lease, cost for the quarter ending 2019-06-30 was $830.00K.
- SYNLOGIC, INC. operating lease, cost for the quarter ending 2019-03-31 was $694.00K.
- SYNLOGIC, INC. operating lease, cost for fiscal 2024 was $1.58M, a 67.51% decline from fiscal 2023.
- SYNLOGIC, INC. operating lease, cost for fiscal 2023 was $4.87M, a 1.18% increase from fiscal 2022.
- SYNLOGIC, INC. operating lease, cost for fiscal 2022 was $4.81M, a 25.84% increase from fiscal 2021.
- SYNLOGIC, INC. operating lease, cost for fiscal 2021 was $3.82M, a 5.40% increase from fiscal 2020.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.58M 10-K · filed 2025-03-06 | |||
| 2023-12-31 | $4.87M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $4.81M 10-K · filed 2024-03-19 | |||
| 2021-12-31 | $3.82M 10-K · filed 2023-03-29 | |||
| 2020-12-31 | $3.63M 10-K · filed 2022-03-17 | |||
| 2019-12-31 | $907.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.81M derived: sum of 2 quarters · filed 2021-03-25 | $2.64M derived: sum of 3 quarters · filed 2021-03-25 | $3.34M 10-K · filed 2021-03-25 |
| 2019-09-30 | $907.00K 10-Q · filed 2019-11-12 | $1.74M derived: sum of 2 quarters · filed 2019-11-12 | $2.44M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $830.00K 10-Q · filed 2019-08-08 | $1.52M 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $694.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |